NDAINHALATIONPOWDER
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
INBRIJA (levodopa) by Merz Therapeutics is levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. First approved in 2018.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INBRIJA is an inhaled levodopa powder approved in December 2018 for treating motor fluctuations in Parkinson's disease patients already on oral levodopa therapy. Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinsonian symptoms through rapid onset inhalation delivery. This novel inhalation route provides an alternative to traditional oral dosing, enabling faster symptom relief during off-episodes.
$0.027BPart D
Peak7.3 years to LOEProduct is at peak lifecycle stage with modest Part D spend suggesting niche market penetration; brand team likely operates lean with focused commercial infrastructure.
Mechanism of Action
Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
Pharmacologic Class:
Aromatic Amino Acid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease
Started May 2026
215 enrolled
Advanced Parkinson Disease
A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium
Started Mar 2026
120 enrolled
Parkinson's Disease
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
Started Mar 2026
100 enrolled
Parkinson's Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Started Feb 2026
150 enrolled
Parkinson Disease
A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa
Started Nov 2025
103 enrolled
Advanced Parkinson's Disease
Worked on INBRIJA at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.